Imperial College London
Portrait Picture

Dr Frédéric B. Piel

Faculty of Medicine, School of Public Health

Senior Lecturer
 
 
 
//

Contact

 

f.piel

 
 
//

Location

 

1112Sir Michael Uren HubWhite City Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Piel:2017:10.1016/j.bcmd.2017.08.017,
author = {Piel, FBJ and Rigano, P and De, Francesci L and Sainati, L and Piga, A and Cappellini, MD and Fidone, C and Masera, N and Palazzi, G and Gianesin, B and Forni, GL},
doi = {10.1016/j.bcmd.2017.08.017},
journal = {Blood Cells, Molecules and Diseases},
pages = {82--89},
title = {Real-life experience with hydroxyurea in sickle cell disease: A multicenter study in a cohort of patients with heterogeneous descent},
url = {http://dx.doi.org/10.1016/j.bcmd.2017.08.017},
volume = {69},
year = {2017}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - We conducted the first nation-wide cohort study of sickle cell disease (SCD) in Italy, a Southern European country exposed to intense recent flux migration from endemic areas for SCD. We evaluate the impact of hydroxyurea on a total of 652 pediatric and adult patients from 33 Reference Centers for SCD (mean age 24.5 ± 15 years, 51.4% males). Hydroxyurea median treatment duration was 7 years (range: < 1 year to 29 years) at a mean therapeutic dose of 18 ± 4.7 mg/kg/day. Hydroxyurea was associated with a significant increase in mean total and fetal hemoglobin and a significant decrease in mean hemoglobin S, white blood and platelet counts, and lactate dehydrogenase levels. Hydroxyurea was associated with a significant reduction in the incidence of acute chest syndrome (− 29.3%, p < 0.001), vaso-occlusive crisis (− 34.1%, p < 0.001), hospitalization (− 53.2%, p < 0.001), and bone necrosis (− 6.9%, p < 0.001). New silent cerebral infarction (SCI) occurred during treatment (+ 42.4%, p < 0.001) but not stroke (+ 0.5%, p = 0.572). These observations were generally consistent upon stratification for age, descent (Caucasian or African), genotype (βS/βS, βS/β0 or βS/β+) and duration of treatment (< or ≥ 10 years). There were no new safety concerns observed compared to those commonly reported in the literature. Our study, conducted on a large population of patients with different descent and compound state supports the benefits of hydroxyurea therapy as a treatment option. Registered at clinical trials.gov (NCT02709681).
AU  - Piel,FBJ
AU  - Rigano,P
AU  - De,Francesci L
AU  - Sainati,L
AU  - Piga,A
AU  - Cappellini,MD
AU  - Fidone,C
AU  - Masera,N
AU  - Palazzi,G
AU  - Gianesin,B
AU  - Forni,GL
DO  - 10.1016/j.bcmd.2017.08.017
EP  - 89
PY  - 2017///
SN  - 1079-9796
SP  - 82
TI  - Real-life experience with hydroxyurea in sickle cell disease: A multicenter study in a cohort of patients with heterogeneous descent
T2  - Blood Cells, Molecules and Diseases
UR  - http://dx.doi.org/10.1016/j.bcmd.2017.08.017
UR  - http://hdl.handle.net/10044/1/51635
VL  - 69
ER  -
Download